Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00276770
- Lead Sponsor
- University of Washington
- Brief Summary
RATIONALE: Diagnostic procedures, such as positron emission tomography using fluorothymidine F 18, may be effective in finding recurrent disease in patients with gliomas.
PURPOSE: This clinical trial is studying how well positron emission tomography using fluorothymidine F 18 works in finding recurrent disease in patients with gliomas.
- Detailed Description
OBJECTIVES:
Primary
* Determine the safety of fluorothymidine F 18 for visual and dynamic brain tumor images in patients with glial neoplasms.
* Determine, preliminarily, the efficacy of this drug.
Secondary
* Compare, preliminarily, the efficacy of this drug to fludeoxyglucose F 18 in differentiating tumor recurrence from radiation necrosis.
* Determine the optimal time to image post injection of this drug.
OUTLINE: This is a pilot, nonrandomized study.
Patients receive fluorothymidine F 18 IV over 1 minute and then undergo positron emission tomography (PET) scanning of the brain over 2 hours.
After completion of the PET scan, patients are followed for at least 1 month.
PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Cancer Center at University of Washington Medical Center
🇺🇸Seattle, Washington, United States